PROGLUMETACIN

Details

Stereochemistry	RACEMIC
Molecular Formula	C46H58ClN5O8
Molecular Weight	844.434
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)CC2=C(C)N(C(=O)C3=CC=C(Cl)C=C3)C4=C2C=C(OC)C=C4)CC1)NC(=O)C5=CC=CC=C5

InChI

InChIKey=PTXGHCGBYMQQIG-UHFFFAOYSA-N

InChI=1S/C46H58ClN5O8/c1-5-21-51(22-6-2)46(57)40(48-44(55)34-11-8-7-9-12-34)18-20-42(53)59-29-10-23-49-24-26-50(27-25-49)28-30-60-43(54)32-38-33(3)52(41-19-17-37(58-4)31-39(38)41)45(56)35-13-15-36(47)16-14-35/h7-9,11-17,19,31,40H,5-6,10,18,20-30,32H2,1-4H3,(H,48,55)

HIDE SMILES / InChI

Description
Sources: http://www.mims.com/philippines/drug/info/proglumetacin?mtype=generic
Curator's Comment: Description was created based on several sources, including http://www.druginfosys.com/drug.aspx?drugcode=980&drugname=&type=2 https://www.ncbi.nlm.nih.gov/pubmed/2826180

Proglumetacin (usually as the maleate salt, trade names Afloxan, Protaxon and Proxil) is a non-steroidal anti-inflammatory drug. Proglumetacin is indicated for the pain and inflammation associated with musculoskeletal and joint disorders. The action of proglumetacin maleate is qualitatively the same as that of indomethacin in vivo; that is, it inhibits cyclo-oxygenase in inflammatory sites.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-2 196 Target ID: CHEMBL230 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D08427 \| http://www.druginfosys.com/drug.aspx?drugcode=980&drugname=&type=2	Inhibitor 8297
Cyclooxygenase-1 127 Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D08427 \| http://www.druginfosys.com/drug.aspx?drugcode=980&drugname=&type=2	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Musculoskeletal and joint disorders 3 Sources: http://www.mims.com/philippines/drug/info/proglumetacin?mtype=generic	Palliative		Approved 8429	Afloxan Approved Use Pain and inflammation associated with musculoskeletal and joint disorders.

PubMed

Title	Date	PubMed
Pharmacological studies on proglumetacin maleate, a new non-steroidal anti-inflammatory drug (4). Mode of action on anti-inflammatory activity.	1986 Nov	3102823

Patents

Sample Use Guides

In Vivo Use Guide

Oral Pain and inflammation associated with musculoskeletal and joint disorders Adult: Up to 600 mg/day in divided doses.

Route of Administration: Oral

In Vitro Use Guide

PGM (IC50 = 1.5 uM) strongly inhibited 5-HETE formation by the cytosol of guinea pig polymorphonuclear leukocytes.

Name

Type

Language

PROGLUMETACIN

Official Name

English

3-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)PROPYL DL-4-BENZAMIDO-N,N-DIPROPYLGLUTARAMATE 1-(P-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETATE (ESTER)

Common Name

English

5-(DIPROPYLAMINO)-1,5-DIOXOPENTYL)OXY)PROPYL)-1-PIPERAZINYL)ETHYL ESTER, (±)-

Common Name

English

PROGLUMETACIN [MI]

Common Name

English

Proglumetacin [WHO-DD]

Common Name

English

1H-INDOLE-3-ACETIC ACID, 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-, 2-(4-(3-((4-(BENZOYLAMINO)-

Common Name

English

proglumetacin [INN]

Common Name

English

1H-INDOLE-3-ACETIC ACID, 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-, 2-(4-(3-((4-(BENZOYLAMINO)-5-(DIPROPYLAMINO)-1,5-DIOXOPENTYL)OXY)PROPYL)-1-PIPERAZINYL)ETHYL ESTER

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QM01AB14